Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1/2 open-label study of BMS-986466 with adagrasib with or without cetuximab in advanced KRAS G12C-mutant solid tumors
MOH_2023-08-15_012880Phase 2Not yet recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Aug 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of BMS-986466, adagrasib and cetuximab in non-small cell lung cancer (NSCLC), pancreatic adenocarcinoma (PDAC), biliary cancer and 1 more (6 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Dose-limiting toxicities, Adverse events and 4 more. Planned start Aug 2023; status: not yet recruiting.
02
Drugs
BMS-986466adagrasibcetuximab
03
Conditions
non-small cell lung cancer (NSCLC)pancreatic adenocarcinoma (PDAC)biliary cancercolorectal cancer (CRC)
Beyond the preview
Go deeper on MOH_2023-08-15_012880.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2023-08-15_012880.